Arvinas (ARVN) Competitors $9.46 +0.05 (+0.53%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$9.44 -0.02 (-0.16%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN vs. OGN, BEAM, ALVO, CPRX, MLYS, BLTE, GLPG, CDTX, IDYA, and IRONShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Organon & Co. (OGN), Beam Therapeutics (BEAM), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Mineralys Therapeutics (MLYS), Belite Bio (BLTE), Galapagos (GLPG), Cidara Therapeutics (CDTX), IDEAYA Biosciences (IDYA), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Its Competitors Organon & Co. Beam Therapeutics Alvotech Catalyst Pharmaceuticals Mineralys Therapeutics Belite Bio Galapagos Cidara Therapeutics IDEAYA Biosciences Disc Medicine Arvinas (NASDAQ:ARVN) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings. Does the media refer more to ARVN or OGN? In the previous week, Arvinas had 5 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Arvinas and 2 mentions for Organon & Co.. Arvinas' average media sentiment score of 0.60 beat Organon & Co.'s score of 0.40 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ARVN or OGN? Arvinas currently has a consensus price target of $16.18, suggesting a potential upside of 71.08%. Organon & Co. has a consensus price target of $17.33, suggesting a potential upside of 81.54%. Given Organon & Co.'s stronger consensus rating and higher possible upside, analysts plainly believe Organon & Co. is more favorable than Arvinas.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 2 Sell rating(s) 10 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.43Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has preferable valuation & earnings, ARVN or OGN? Organon & Co. has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$263.40M2.64-$198.90M-$1.01-9.37Organon & Co.$6.40B0.39$864M$2.693.55 Do insiders and institutionals believe in ARVN or OGN? 95.2% of Arvinas shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 4.7% of Arvinas shares are held by insiders. Comparatively, 2.0% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is ARVN or OGN more profitable? Organon & Co. has a net margin of 11.15% compared to Arvinas' net margin of -19.47%. Organon & Co.'s return on equity of 163.88% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets Arvinas-19.47% -12.01% -6.97% Organon & Co. 11.15%163.88%6.99% Which has more volatility & risk, ARVN or OGN? Arvinas has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. SummaryOrganon & Co. beats Arvinas on 9 of the 16 factors compared between the two stocks. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$690.86M$3.36B$6.11B$10.45BDividend YieldN/A2.30%5.73%4.77%P/E Ratio-9.3722.7785.4027.36Price / Sales2.64483.38599.20137.65Price / CashN/A46.7037.4661.86Price / Book1.1610.5512.446.81Net Income-$198.90M-$52.58M$3.32B$276.80M7 Day Performance-1.36%0.09%0.60%0.42%1 Month Performance23.82%15.61%10.53%7.86%1 Year Performance-65.97%15.13%73.12%41.24% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas3.0273 of 5 stars$9.46+0.5%$16.18+71.1%-63.5%$690.86M$263.40M-9.37420Analyst ForecastGap DownOGNOrganon & Co.4.8073 of 5 stars$10.84-1.5%$17.33+59.9%-47.1%$2.82B$6.40B4.034,000BEAMBeam Therapeutics3.1278 of 5 stars$25.89+0.5%$46.40+79.2%+3.2%$2.62B$63.52M-5.75510ALVOAlvotech3.6292 of 5 stars$8.58+3.1%$14.00+63.2%-28.2%$2.59B$560.10M37.301,032Analyst UpgradeGap UpCPRXCatalyst Pharmaceuticals4.8014 of 5 stars$20.73-0.5%$33.20+60.2%+0.4%$2.54B$491.73M12.5680MLYSMineralys Therapeutics1.7881 of 5 stars$38.01-0.1%$43.50+14.4%+216.4%$2.52BN/A-10.6828News CoverageInsider TradeBLTEBelite Bio2.2695 of 5 stars$78.10+3.3%$96.00+22.9%+46.5%$2.49BN/A-50.3910High Trading VolumeGLPGGalapagos0.3273 of 5 stars$35.55-5.5%$26.00-26.9%+16.0%$2.48B$275.61M0.001,310Upcoming EarningsCDTXCidara Therapeutics4.0855 of 5 stars$96.45-5.4%$122.29+26.8%+938.5%$2.45B$1.27M-8.6790IDYAIDEAYA Biosciences4.0256 of 5 stars$27.49-0.5%$43.36+57.7%-7.9%$2.41B$7M-7.2580IRONDisc Medicine2.4428 of 5 stars$69.28+2.2%$98.30+41.9%+61.6%$2.41BN/A-15.5030 Related Companies and Tools Related Companies OGN Competitors BEAM Competitors ALVO Competitors CPRX Competitors MLYS Competitors BLTE Competitors GLPG Competitors CDTX Competitors IDYA Competitors IRON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARVN) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
